Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis

  title={Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis},
  author={Xinbin Zhou and Jin Dai and Xiao-ming Xu and Zhijun Wang and Haibin Xu and Jie Chen and Yuangang Qiu and Wei Mao},
  pages={305 - 316}
Contrast-induced acute kidney injury (CI-AKI) is a common complication of iodinated contrast medium administration during cardiac catheterization. [] Key Method We systematically searched several databases (including, Embase, PubMed, the Cochrane Library, and from inception to January 31, 2018. The primary outcome was occurrence of CI-AKI in patients with CKD undergoing cardiac catheterization. Both pairwise and network meta-analysis were performed.

Figures and Tables from this paper

A network meta-analysis on comparative efficacy of statins focusing for prevention of contrast-induced acute kidney injury in chronic kidney disease patients undergoing percutaneus coronary intervention
A network meta-analysis was carried out to evaluate the effect of different statins in prevention of CI-AKI and also to investigate which type and dose of statins maybe the best choice specifically in CKD patients who have higher risk.
Effect of statins on post-contrast acute kidney injury: a multicenter retrospective observational study
Preoperative statins therapy is an independent protective factor of PC-AKI, regardless of its type, and the potential use of statins in preventing PC- AKI among those at risk is underscored.
Sodium Bicarbonate versus Statins to Prevent Contrast-induced Acute Kidney Injury: A Comprehensive Review
The objective of this review is to compare the findings of various studies that had applied different doses of statins, sodium bicarbonate, and other agents for preventing CI-AKI.
Contrast-induced nephropathy in non-cardiac vascular procedures, a narrative review: Part 1.
Physicians and vascular surgeons should be aware of CM-related adverse events and the potential strategies to avoid them, as well as preventive strategies and alternatives to limit iodinated CM use.
Pharmacologic Prophylaxis of Contrast-Induced Nephropathy.
Contrast-Induced Acute Kidney Injury: Review and Practical Update
The pathophysiology, predictors, and clinical management of CI-AKI are addressed with a concise overview and a suggested association with left atrial appendage closure is suggested.
In-Hospital Bleeding in Elderly Patients With Acute Coronary Syndrome: Are Potent Antiplatelet Agents Safe?
Ticagrelor and tirofiban should be used with caution in elderly ACS patients, as the urinary tract was the most frequent bleeding site, followed by femoral arteries.
Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know.
Physicians should keep in mind the pivotal role of cholesterol levels in determining cardiovascular outcomes and the pleiotropic beneficial effects associated with statin use and should not miss the opportunity for cardiovascular risk reduction with aggressive statin treatment.
Contrast-Induced Nephropathy after Endovascular Aneurysm Repair, Carotid and Peripheral Interventions.
The increasing use of endovascular procedures in the last few years has led to more interventions requiring contrast media. This has led to an increase in the incidence of contrast-induced


Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
The Role of Statins in Preventing Contrast-Induced Acute Kidney Injury
It is uncertain whether statins should be prescribed to prevent CI-AKI in the absence of other indications, and there are also conflicting results.
Contrast-Induced Acute Kidney Injury Is Associated With Long-Term Adverse Events in Patients With Acute Coronary syndrome
Patients with acute coronary syndrome who developed CI-AKI have worse prognosis at long-term follow-up and additional preventive treatment strategies need to be developed in this group of patients.
Contrast medium induced acute kidney injury: a narrative review
Pre-existing CKD, intra-arterial administration and CM volume are the most important risk factors for CI-AKI, and patients should be carefully stratified before the administration of CM, to reduce the negative impact of modifiable risk factors on renal function.
Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
Rosuvastatin and atorvastatin have similar efficacies for preventing CIN in patients with CKD undergoing PCI, after adjusting for potential confounding risk factors.
Statins in prevention of contrast-induced nephropathy in patients with coronary heart disease and renal insufficiency undergoing percutaneous coronary intervention
A short-term administration of high doses of atorvastatin before and after contrast exposure fails to decrease CIN occurrence in CHD patients with pre-existing renal insufficiency.
Pro: Contrast-induced nephropathy—should we try to avoid contrast media in patients with chronic kidney disease?
  • M. WindpesslA. Kronbichler
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2018
Despite considerable progress in the field, the risk of CI-AKI is still high in the modern era and that CM-based imaging should be employed with great restraint in patients with CKD, and there is conceded that there is always a trade-off.